Can a simple antibody infusion stop CMV in kidney transplants?
NCT ID NCT07096453
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 38 times
Summary
This study tests whether an antibody drug called CMVIG (Cytogam) can prevent cytomegalovirus (CMV) infection in kidney transplant patients who are switching to a newer immunosuppressant, belatacept. Researchers will measure CMV antibody levels in 30 adult recipients over 8 weeks. The goal is to see how the drug behaves in the body and if it might reduce infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cytogam (CMVIG)
What this could lead to
If it works, this could help prevent CMV infection in kidney transplant patients, reducing complications.
What could go wrong
This is a very small early-phase pilot study with only 30 participants. It is not yet known if CMVIG effectively reduces CMV levels or prevents infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.